Hydrogen sulfide in diabetes and cardiovascular disease
van den Born, Joost Christiaan

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism

Pauline M. Snijder
Rudolf A. de Boer
Eelke M. Bos
Joost C. van den Born
Willem-Peter Ruifrok
Inge Vreeswijk – Baudoin
Marcory C.R.F. van Dijk
Jan-Luuk Hillebrands
Henri G.D. Leuvenink
Harry van Goor
Ischemia-reperfusion injury (IRI) is a major cause of cardiac damage following various pathological processes. Gaseous hydrogen sulfide (H\textsubscript{2}S) is protective during IRI by inducing a hypometabolic state in mice that is associated with anti-apoptotic, anti-inflammatory and antioxidant properties. We investigated whether gaseous H\textsubscript{2}S administration is protective in cardiac IRI and whether non-hypometabolic concentrations of H\textsubscript{2}S have similar protective properties.

Male C57BL/6 mice received a 0, 10, or 100 ppm H\textsubscript{2}S-N\textsubscript{2} mixture starting 30 minutes prior to ischemia until 5 min pre-reperfusion. IRI was inflicted by temporary ligation of the left coronary artery for 30 min. High-resolution respirometry equipment was used to assess CO\textsubscript{2}-production and blood pressure was measured using internal transmitters. The effects of H\textsubscript{2}S were assessed by histological and molecular analysis.

Treatment with 100 ppm H\textsubscript{2}S decreased CO\textsubscript{2}-production by 72%, blood pressure by 14% and heart rate by 25%, while treatment with 10 ppm had no effects. At day 1 of reperfusion 10 ppm H\textsubscript{2}S showed no effect on necrosis, while treatment with 100 ppm H\textsubscript{2}S reduced necrosis by 62% (P<0.05). Seven days post-reperfusion, both 10 ppm (P<0.01) and 100 ppm (P<0.05) H\textsubscript{2}S showed a reduction in fibrosis compared to IRI animals. Both 10 ppm and 100 ppm H\textsubscript{2}S reduced granulocyte-influx by 43% (P<0.05) and 60% (P<0.001), respectively. At 7 days post-reperfusion both 10 and 100 ppm H\textsubscript{2}S reduced expression of fibronectin by 63% (P<0.05) and 67% (P<0.01) and ANP by 84% and 63% (P<0.05), respectively.

Gaseous administration of H\textsubscript{2}S is protective when administered during an cardiac ischemic insult. Although hypometabolism is restricted to small animals, we now showed that low non-hypometabolic concentrations of H\textsubscript{2}S also have protective properties in IRI. Since IRI is a frequent cause of myocardial damage during percutaneous coronary intervention and cardiac transplantation, H\textsubscript{2}S treatment might lead to novel therapeutic modalities.
Gaseous H$_2$S is protective in myocardial I/R injury

Introduction

Ischemia-reperfusion injury (IRI) is the most important cause of myocardial damage and subsequent heart failure. Although IRI is most frequently caused by acute myocardial infarction (MI) with (early or late) reperfusion, it can also be observed following surgical procedures such as cardiopulmonary bypass or cardiac transplantation.$^1,2$ Myocardial IRI causes acute tissue responses characterized by inflammation and upregulation of inflammatory mediators. This process ultimately leads to irreversible fibrotic damage.$^3,4$ Despite major therapeutic developments, cardiovascular disease remains the leading cause of death in the western world.$^5$

Hydrogen sulfide (H$_2$S) has drawn considerable attention for its role in various (patho)physiological processes. It is, in addition to nitric oxide and carbon monoxide, acknowledged as the third gasotransmitter, sharing many functions with these gases.$^6$ H$_2$S is endogenously produced and exerts fine, modulatory control over cellular functions by influencing an array of intracellular signaling processes. H$_2$S-producing enzymes and H$_2$S-plasma levels are reduced in various diseases.$^7-9$ Exogenously administered H$_2$S can reversibly induce a hypometabolic state in mice, during which it rapidly reduces O$_2$-consumption, CO$_2$-production, core body temperature, heart rate and breathing frequency.$^{10,11}$

The most probable mechanism for these properties is the reversible inhibition of mitochondrial O$_2$-consumption and ATP-production through non-permanent binding of sulfide to the terminal enzyme in the electron transport chain, cytochrome c oxidase (complex IV).$^{12}$ It was thought that the reduced demand for oxygen during hypometabolism might be one of the protective mechanisms during ischemia. However, H$_2$S is also considered protective during other processes critically involved in myocardial IRI such as oxidation, inflammation and apoptosis. These cytoprotective features of H$_2$S make it an attractive candidate for therapeutic reduction of the damaging effects of hypoxia.$^{13,14}$

The influence of gaseous administration of H$_2$S and the effects of hypometabolic and non-hypometabolic concentrations on the outcome of myocardial IRI remains to be elucidated. Some studies have explored the beneficial effects of soluble H$_2$S donors such as NaHS and Na$_2$S in myocardial IRI and other models of cardiac damage.$^{15-18}$ The preference for gaseous administration above injection with H$_2$S donors lies within accurate management of the concentration. As opposed to injection with soluble H$_2$S donors, gaseous H$_2$S is less difficult to dose and has a short wash-out period, leaving its positive effects behind.$^{11}$ Moreover, gaseous administration has proven to induce a
hypometabolic state, while this has not been shown for intra-peritoneal or intra-venous administration of soluble H$_2$S.\textsuperscript{10,11} Although H$_2$S does not appear to have hypometabolic effects in ambienly cooled large mammals, thereby questioning its therapeutic applications in humans, the beneficial effects of non-hypometabolic concentrations of H$_2$S have not been studied.\textsuperscript{19,20} Since minimizing myocardial IRI has broad clinical implications and may have beneficial effects on cardiac surgical outcomes,\textsuperscript{1} we therefore investigated whether gaseous H$_2$S-treatment attenuates myocardial IRI in mice and whether non-hypometabolic concentrations exhibit similar protective properties.

### Materials and Methods

#### Ethics Statement

Procedures were in agreement with institutional and legislator regulations and approved by the Committee on the Ethics of Animal Experiments of the University Medical Center Groningen. Utmost effort was utilized to prevent suffering and minimize the numbers of mice required for each experiment.

#### Animals

Male C57BL/6 mice (6-8 weeks, Harlan, Zeist, the Netherlands) were housed at our animal research facility under standard conditions with a 12h light:dark cycle with free access to water and chow.

#### Telemetry

Blood pressure was measured telemetrically (n=4) using transmitters (TA11PA-C10; Data Sciences International, St Paul, MN, USA). Devices were placed through a midline abdominal incision under anesthesia (2% Isoflurane) and mice were placed on a heating pad to maintain body temperature at 37°C. The catheter was placed in the aorta and the transmitter body in the abdominal cavity. Animals recovered 7 days before commencing measurements. Data were recorded as 10-second averages every minute using Dataquest ART data acquisition system (Data Sciences International). Animals were treated with room air or a H$_2$S/ air mixture in our respirometry system during measurements. For comparison of blood pressure and heart rate, the average of 20 minutes baseline measurement and 20 minutes of 10 ppm and 100 ppm H$_2$S treatment was determined. A crossover design was
Gaseous H\textsubscript{2}S is protective in myocardial I/R injury

used in which all animals received all treatments in randomized order.

**Respirometry**

Measurement of CO\textsubscript{2}-production was performed as described. Compressed air and 500 ppm H\textsubscript{2}S / N\textsubscript{2} (Air Products, Amsterdam, the Netherlands) were mixed in a 4:1 ratio and in a 49:1 ratio resulting in a 100 ppm H\textsubscript{2}S / 17% O\textsubscript{2} mixture and a 10 ppm H\textsubscript{2}S / 17% O\textsubscript{2} mixture, respectively. CO\textsubscript{2}-production was corrected for body weight and normalized to mean control values. Animals (n=11) were treated in a crossover model in randomized order and all received room air, 10 ppm H\textsubscript{2}S and 100 ppm H\textsubscript{2}S on different days. Baseline CO\textsubscript{2} measurements with room air were performed for 30 minutes followed by treatment with either a 10 or 100 ppm H\textsubscript{2}S / 17% O\textsubscript{2} mixture for 30 minutes. Recovery with room air was measured for 30 minutes.

**Myocardial ischemia/reperfusion and H\textsubscript{2}S treatment**

Mice were intubated and mechanically ventilated (n=77) with an O\textsubscript{2} / N\textsubscript{2} mixture in a 4:1 ratio, an O\textsubscript{2} / 100 ppm H\textsubscript{2}S / N\textsubscript{2} mixture in a 4:1 ratio or a O\textsubscript{2} / 10 ppm H\textsubscript{2}S / N\textsubscript{2} mixture in a 49:1 ratio at a frequency of 180/min with a tidal volume of 250 μl using a rodent ventilator (Harvard Midivent model 849). Treatment regimens (Sham n=15; IRI n=20; 10 ppm n=21; 100 ppm n=21) were randomly assigned and started 30 minutes prior to ischemia until 5 minutes pre-reperfusion. Myocardial IRI was inflicted by temporary ligation of the left anterior descending coronary artery (6-0 prolene suture) for 30 min through an incision in the fourth intercostal space under anesthesia (75 mg/kg ketamine, 1 mg/kg medetomidine). After removing the ligature the heart was inspected for restoration of blood flow and muscle and skin layers were sutured with 5.0 vicryl. Body temperature was monitored with a rectal probe and maintained at 37°C using heat pads. Sham operated animals underwent the same procedure, except the placement of the ligature. Post-operatively, all mice received a subcutaneous injection of 50 μg/kg buprenorphin (Schering-Plough) for analgesic purposes and were allowed to recover from surgery at 37°C in a ventilated incubator. After 1 and 7 days mice were anaesthetized with 2% isoflurane in O\textsubscript{2} for collection of blood and organs. Blood was collected in heparin containing tubes, centrifuged for 10 minutes at 1000 rcf and plasma was collected and stored at -80°C. The hearts were rapidly excised and mid-papillary slices were fixed in 4% paraformaldehyde, paraffin-embedded and sections were cut for immunohistochemical analysis. Apical parts of the heart were snap frozen in liquid nitrogen and stored at -80°C for molecular analysis.
Plasma analysis
Cardiac damage was assessed by measuring high sensitive (hs) Troponin-T in plasma samples using a standard electrochemiluminescence immunoassay (Roche) in the clinical chemical laboratory.

Histopathological scoring
At 1 day of reperfusion the extent of necrosis was determined in haematoxylin-eosin stained sections. At 7 days of reperfusion the extent of fibrosis was determined in Masson stained sections. Both were examined in a blinded fashion. Sections were scanned using an Aperio ScanScope GS (Aperio Technologies, Vista, CA, USA). Total cardiac area, necrotic cardiac area and fibrotic cardiac area were determined using Aperio Imagescope software, and the ratio of necrotic cardiac surface area and fibrotic surface area to total cardiac surface area were determined. Representative photomicrographs were artificially colored indicating the extent of damage.\textsuperscript{11,21}

Immunohistochemistry for Ly-6G
For granulocytes, paraffin-embedded sections were stained for Ly-6G using rat-anti-mouse Ly6G/C-FITC IgG2b antibody (AbCam, Cambridge, MA, USA), followed by rabbit-anti-FITC and HRP-conjugated goat-anti-rabbit antibodies. Slides were scanned using an Aperio ScanScope GL (Aperio Technologies, Vista, CA, USA) and analyzed for positive pixel area (Ly-6G) using the Aperio Positive Pixel Analysis v9.1 algorithm.

Qualitative Real-Time Polymerase Chain Reaction
RNA extraction, DNAse treatment\textsuperscript{21} and cDNA synthesis\textsuperscript{22} were performed as described. A relative quantification PCR was performed to determine gene expression (Applied Biosystems, Foster City, CA). b-actin and GAPDH were used as housekeeping genes. The primers used were:

Fibronectin (NM_010233.1)
- Forward: AGGAAATGTACTGAATGCTAGTACCCA
- Reverse: TCAGATGGCAAAAGAAAGCAGA

ANP (NM_008725.2)
- Forward: ACCCTCCTGGAGCTGCG
- Reverse: ACCCCCCTAGACCACCTCATCTACAT
Gaseous H$_2$S is protective in myocardial I/R injury

NOX2 (NM_007807.4)
Forward: GATGCAATAAGACTAGGCACAAACC
Reverse: CCATCTCATAACCAGAATAACTCAGGATA

NOX4 (NM_015760.4)
Forward: TGCACCAACACAGAAGCACA
Reverse: AGCAGGGTATCCTCCATGAATTC

PCR was performed in a volume of 20 µl containing 10 ng cDNA and 15 µl PCR mastermix (SYBR GREEN Applied Biosystems; 5 ml P/N 4309155). The Thermal Profile was performed as described. The average Ct-values for fibronectin, ANP, NOX2 and NOX4 were subtracted from the average β-actin Ct-values and the average of β-actin and GAPDH Ct-values to yield the delta Ct. Results were expressed as 2$^{-ΔCt}$.

**Cell culture**
The H9c2 cell line (ATCC) is an immortalized line with characteristics of rat heart myoblasts. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Germany) containing 4.5 g/l glucose, 10% fetal calf serum (FCS; Bodinco, Alkmaar, the Netherlands), L-glutamine and penicillin (100 U/ml) streptomycin (100 µg/ml) (Lonza, Germany). Cells were cultured using 75 cm$^2$ collagen coated flasks (Corning, Schiphol-Rijk, Netherlands) in a humidified atmosphere of 5% CO$_2$ and 95% O$_2$ at 37°C.

**In vitro model of oxidative stress**
H9c2 cells grown to 80-90% confluency were harvested using 3 ml trypsin EDTA (200 mg/l) after washing twice with Hank’s Buffered Salt Solution (HBSS) (Lonza; Germany). Cells were cultured in a 24-well plate at a density of ~10.000 cells/well in 0.5 ml medium. After 24 hours cells were loaded with 15 µM Dihydroethidine (DHE). Culture plates were placed in a humidified chamber with 5% CO$_2$ on an automated inverted fluorescent microscope system (TissueFAXS system, TissueGnostics GMBH, Vienna, Austria) which makes sequential photomicrographs of 9 area’s in each well every 5 minutes. After baseline measurements, cells were exposed to Antimycin (50 µg/mL) and NaHS (donor of H$_2$S in solution) in a concentration of 1 mM. Fluorescence intensity of every cell was analyzed using the TissueQuest software (TissueGnostics).
**Statistical analysis**

Data were analyzed using GraphPad PRISM 5.0 (GraphPad, San Diego, CA, USA) using two-way ANOVA, Mann-Whitney U, Friedman or Kruskall Wallis tests where appropriate. Bonferroni or Dunns post-hoc analysis was applied where multiple comparisons were made. Normality was tested using the Kolmogorov–Smirnov test. $P<0.05$ was considered statistically significant. All data are expressed as mean ± SEM (Standard Error of the Mean) unless otherwise indicated.

**Results**

**Effect of H$_2$S on CO$_2$ production, blood pressure and heart rate**

Within 15 minutes of treatment with 100 ppm H$_2$S induced a state of hypometabolism, concomitant with a reduction in CO$_2$-production by an average of 72% compared to basal levels ($P<0.001$). Cessation of H$_2$S resulted in a rapid recovery of CO$_2$-production, where CO$_2$ concentrations raised to basal levels within 30 minutes ($P<0.001$). 100 ppm H$_2$S lowered blood pressure with 14% (103 vs. 120 mmHg, $P<0.05$) and heart rate with 25% compared to baseline (502 vs. 670 beats per minute, $P<0.05$) 10 ppm H$_2$S had no effect on CO$_2$ production, blood pressure and heart rate (Figure 1).

**H$_2$S reduces myocardial damage**

At 1 day of reperfusion cardiac IRI induced significant necrosis (Figure 2A) in animals exposed to 0 ppm H$_2$S when compared to sham animals ($P<0.001$) as indicated by infarct size. 10 ppm H$_2$S did not reduce the size of the necrotic area, while 100 ppm H$_2$S reduced infarct size by 62% ($P<0.05$) (Figure 2B). In mice treated with 10 ppm H$_2$S hs Troponin-T levels were not reduced 1 day post-reperfusion, while 100 ppm H$_2$S reduced hs Troponin-T levels by 47% ($P<0.05$) compared to IRI animals (Figure 2C). Fibrosis, as measured by collagen deposition in Masson stained sections (Figure 3A) at 7 days of reperfusion, was markedly increased in animals treated with 0 ppm H$_2$S when compared to sham-operated animals ($P<0.001$). Treatment with either 10 or 100 ppm of H$_2$S reduced collagen deposition to comparable levels (10 ppm: 59%, $P<0.01$; 100 ppm: 57%, $P<0.05$) (Figure 3B). Cardiac mRNA levels of fibronectin, a marker of myocardial fibrosis, were massively increased in 0 ppm H$_2$S treated animals ($P<0.01$), while no increase was detected in animals of both H$_2$S treated groups (10 ppm H$_2$S $P<0.05$; 100 ppm H$_2$S $P<0.01$) (Figure 3C).
Gaseous H$_2$S is protective in myocardial I/R injury

Seven days post-reperfusion hs Troponin-T levels were reduced by 59% ($P<0.05$) and 75% ($P<0.01$) in 10 ppm and 100 ppm H$_2$S treated mice, respectively (Figure 3D).

**Figure 1** - High concentrations of H$_2$S induce a state of hypometabolism. Within 15 minutes (A) CO$_2$-production decreased by 72% (**P<0.001** in mice (n=11) subjected to 100 ppm H$_2$S. Exposure to 10 ppm H$_2$S (n=11) did not induce a reduction in CO$_2$ production in these animals. Cessation of gaseous H$_2$S resulted in rapid recovery, within 30 minutes CO$_2$ levels returned back to baseline concentrations (**P<0.001). Administration of 100 ppm H$_2$S (n=4) resulted in a 14% decrease in (B) mean arterial pressure and a 25% decrease in (C) heart rate (*$P<0.05$). However exposure to 10 ppm H$_2$S (n=4) had no effect on mean arterial pressure or heart rate.
Figure 2 - Cardiac damage is reduced by 100 ppm H$_2$S at 1 day of reperfusion. (A) Representative photomicrographs of haematoxylin-eosin stained cardiac sections with necrotic area artificially colored red, indicating the extent of necrotic damage found in each group at 1 day of reperfusion. (B) Cardiac IR induced a significant amount of necrosis in IRI animals exposed to 0 ppm H$_2$S (### $P<0.001$ vs. sham). In animals treated with 100 ppm H$_2$S necrosis was reduced by 62% (* $P<0.05$ vs. IRI) whereas 10 ppm H$_2$S had no effect on necrosis. (C) At 1 day of reperfusion hs Troponin-T levels were elevated in IRI animals exposed to 0 ppm H$_2$S (## $P<0.01$ vs. sham). In the 100 ppm H$_2$S treated group hs Troponin-T levels were reduced compared to 0 ppm treated animals (* $P<0.05$), 10 ppm H$_2$S had no effect.

**ANP-gene expression**

mRNA expression of atrial natriuretic peptide (ANP), a marker for induction of the fetal gene program, was significantly increased in hearts of mice treated with 0 ppm H$_2$S compared to sham-operated animals at 7 days of reperfusion. In hearts of 10 and 100 ppm H$_2$S treated mice the relative ANP expression was significantly reduced compared to mice treated with 0 ppm H$_2$S ($P<0.05$) (Figure 3E).

**Inflammation**

One day post-reperfusion, Ly-6G-positive granulocytes were increased 12-fold in animals treated with 0 ppm H$_2$S compared to sham-operated animals ($P<0.001$). Exposure to 10 ppm and 100 ppm H$_2$S reduced granulocytes by 43% ($P<0.05$) and 60% ($P<0.001$), respectively (Figure 4).
Gaseous H$_2$S is protective in myocardial I/R injury

Figure 3 - Cardiac damage is reduced by 10 and 100 ppm H$_2$S at 7 days of reperfusion. (A) Representative photomicrographs of Masson stained cardiac sections with fibrotic area artificially colored red, indicating the extent of fibrotic damage found in each group at 7 days of reperfusion. (B) Cardiac IR induced a significant amount of fibrosis in IRI animals exposed to 0 ppm H$_2$S (### P<0.001 vs. Sham). In animals treated with 10 ppm and 100 ppm H$_2$S fibrosis was significantly reduced (** P<0.01, * P<0.05 vs. IRI). (C) Expression of fibronectin at 7 days of reperfusion was increased in IRI animals (## P<0.01 vs. sham). Treatment with 10 and 100 ppm H$_2$S reduced the expression of fibronectin (* P<0.05, ** P<0.01 vs. IRI). (D) Seven days post-reperfusion hs Troponin-T levels were elevated in IRI animals exposed to 0 ppm H$_2$S (# P<0.01 vs. sham). Both 10 and 100 ppm H$_2$S reduced hs Troponin-T levels by 59% and 75%, respectively, as compared to animals treated with 0 ppm (* P<0.05, ** P<0.01 vs. IRI). (E) Expression of ANP mRNA at 7 days of reperfusion was increased in IRI animals (## P<0.01 vs. Sham). Treatment with 10 and 100 ppm H$_2$S reduced the expression of ANP (* P<0.05 vs. IRI).
Figure 4 - H$_2$S reduces cardiac IRI induced inflammation. There was a marked increase in granulocyte influx after cardiac ischemia (P<0.001) compared to sham animals. Exposure to 10 ppm and 100 ppm H$_2$S significantly reduced the influx of granulocytes in the infarct area (10 ppm P<0.05; 100 pm P<0.001). Below are representative images from these stainings: (A) Sham (B) IRI, 0 ppm H$_2$S (C) IRI, 10 ppm H$_2$S (D) IRI, 100 ppm H$_2$S.
NOX2 and NOX4 gene expression

To investigate ROS-related genes in vivo, we measured mRNA expression of nicotinamide adenine dinucleotide phosphate oxidase 2 and 4 (NOX2 and NOX4). At 1 day of reperfusion no significant differences were found in NOX2 and NOX4 mRNA expression. Seven days post-reperfusion, NOX2 and NOX4 expression were significantly increased in hearts of mice treated with 0 ppm H\textsubscript{2}S compared to sham operated animals (NOX2: \(p<0.05\), NOX4: \(P<0.01\)). NOX2 and NOX4 expression were not amplified in hearts of mice treated with 10 and 100 ppm H\textsubscript{2}S compared to mice treated with 0 ppm H\textsubscript{2}S (\(P<0.05\)) (Figure 5A and B).

Effect of H\textsubscript{2}S on ROS production in vitro

Antimycin A induced ROS production in cultured H9c2 rat cardiomyoblasts was significantly reduced by treatment with NaHS. Live cell imaging of DHE fluorescence showed a massive increase in cytoplasmatic ROS production during treatment with Antimycin, whereas addition of NaHS to the medium markedly reduced this fluorescence signal (\(P<0.001\)) (Figure 6).

![Figure 5: H\textsubscript{2}S attenuates NOX2 and NOX4 upregulation. Expression of (A) NOX2 and (B) NOX4 mRNA was increased in IRI animals at 7 days post-reperfusion (NOX2: \# \(P<0.05\), NOX4: ## \(P<0.01\) vs. Sham). Treatment with 10 and 100 ppm H\textsubscript{2}S reduced the expression of both genes (*\(P<0.05\) vs. IRI). After 1 day of reperfusion no differences were observed between all groups.](image-url)
Figure 6 - H$_2$S reduces ROS production in cultured cardiomyoblasts. (A) Antimycin (50 µg/ml) significantly induced ROS production in H9c2 cells from 24 minutes onwards compared to untreated control cells. Addition of 1 mM NaHS prevented the increase in ROS production. (# $P<0.001$ vs. control; * $P<0.001$ vs. NaHS) (B) Representative photomicrographs of DHE stained H9c2 cells treated with antimycin and NaHS showing less DHE staining (red) in the NaHS treated cells as compared to cells treated with only antimycin.
Discussion

The major finding of this study is that administration of hypometabolic concentrations of gaseous H$_2$S during myocardial IR limits the extent of myocardial damage. Furthermore, non-hypometabolic concentrations of H$_2$S do not seem protective in the early phase after myocardial infarction, but attenuate ischemia associated processes such as fibrosis and ROS formation. Gaseous administration of H$_2$S appears to be an effective way to attenuate the outcome of myocardial IRI, with multiple mechanisms seemingly underlying the protective properties.

H$_2$S is cytoprotective during hypoxia in multiple organs. Beneficial effects of H$_2$S treatment have been reported in models of shock$^{23}$ and intestinal$^{24}$, pulmonary$^{25}$, hepatic$^{21,26}$ and renal ischemia.$^{11}$ The cardio-protective effects of H$_2$S have been demonstrated in models of myocardial injury. However, most of these studies use injection with soluble H$_2$S donor compounds such as sodium hydrosulfide (NaHS) or sodium sulfide (Na$_2$S), while no results have been published on gaseous H$_2$S.$^{15-18,27}$ Gaseous administration might be applicable in patients who are being ventilated because of cardiogenic shock, a state of brain death or during transplantation procedures. Inhaled H$_2$S has beneficial effects in endotoxin induced systemic inflammation$^{28}$ and in experimental Parkinson's disease.$^{29}$ We previously showed protective effects of gaseous H$_2$S during renal and hepatic IRI.$^{11,21}$ The benefits of gaseous administration compared to injections with soluble H$_2$S donors lay within the management of the concentration. As opposed to injection with H$_2$S donors it is possible to administer the gas continuously with a stable dose over longer periods of time. Furthermore, when treatment is stopped the effects vanish rapidly while leaving its positive therapeutic effects behind. Also, gaseous administration at higher concentrations has proven to induce a hypometabolic, hibernation-like state in small animals like rodents.$^{10,11}$

As previously shown, 100 ppm H$_2$S induces a hypometabolic state and lowers blood pressure, heart rate and CO$_2$-production, whereas 10 ppm H$_2$S does not.$^{10,11,30}$ A suspended animation-like state induced by H$_2$S protects mice from lethal hypoxia for periods up to 6 hours,$^{31}$ suggesting that the induction of regulated, reversible and well-controlled hypometabolism in organs holds clinical promise in ischemia-reperfusion related damage where oxygen demand exceeds oxygen availability. Although there was no difference in cardiac necrosis between the 10 ppm treated group and 0 ppm treated group, treatment with 100 ppm significantly reduced necrosis at 1 day of reperfusion. High-sensitive
Chapter 5

Troponin-T (hsTnT) levels in serum were in line with this finding. This suggests that H$_2$S in non-hypometabolic concentrations is not effective in preventing short-term necrosis caused by ischemia, and that the additional value of H$_2$S-induced hypometabolism lies in the early phase of IRI. Although, the protective effects of 100 ppm H$_2$S on necrosis might also be caused by a larger amount of H$_2$S leading to increased anti-oxidant effects, it is difficult to distinguish between the effects of hypometabolism and other effects attributed to a higher dose. However, inducing a suspended animation-like state might be restricted to small animals like rodents. The applicability of hypometabolism in larger animals is still under debate and we are far from developing therapeutic applications in reducing metabolic rate in the clinical setting with the use of H$_2$S.$^{19,20,32,33}$

There are a number of potential mechanisms through which H$_2$S may exert its cardioprotective effects. Both 10 and 100 ppm of H$_2$S were proven anti-inflammatory as evidenced by reduced granulocyte influx into necrotic areas. Treatment with H$_2$S also lowered the influx of granulocytes after renal IRI.$^{11}$ Furthermore, H$_2$S inhibits neutrophil adhesion and activation in response to inflammatory stimuli and suppresses the release of the pro-inflammatory mediator tumor necrosis factor-alpha.$^{34,35}$ Other studies report that H$_2$S mediates pro-inflammatory effects by potentiating sulfide production in neutrophils$^{36}$ and mediating leukocyte activation.$^{37}$ Although granulocyte influx seems to be reduced by treatment with H$_2$S, literature is inconclusive on the contribution of neutrophil invasion to final myocardial infarct size and appears not to be a dominant factor.$^{38}$

We show that treatment with H$_2$S protects against fibrosis at day 7 of reperfusion, as evidenced by reduced collagen deposition and fibronectin expression. Interestingly, the amount of necrosis differs between 10 and 100 ppm H$_2$S at day 1 of reperfusion, but this does not translate into differences in fibrotic area size after 7 days. This indicates that treatment with both concentrations of H$_2$S attenuate the onset of fibrosis. The prevention of fibrosis is in accordance with previous literature showing decreased cardiac remodeling and fibrosis in models of myocardial infarction and heart failure after H$_2$S treatment.$^{15,39,40}$ Although we find reduced fibrosis with both concentrations of H$_2$S, a balanced development of fibrosis remains essential. Suppressed fibrosis with no reduction in the extent of necrosis predisposes to infarct expansion and tissue rupture.$^{41}$ Since 10 ppm H$_2$S does not affect necrosis 1 day post-reperfusion, the anti-fibrotic effects at day 7 of reperfusion are not beneficial per se.

Another functional property of H$_2$S relates to the inhibition of ROS production, since the imbalance in redox status and oxidative stress contributes to fibrosis.$^{42}$ ROS-generating
NOX2 and NOX4 are both increased after ischemic events in experimental models and their deficiency is protective in these models.\textsuperscript{43,44} Seven days post-reperfusion, we found attenuated expression of NOX2 and NOX4 in both H\textsubscript{2}S treated groups indicating less ROS production in vivo. We did not find an alteration of these genes at 1 day of reperfusion, which is in concordance with previous literature concerning NOX2.\textsuperscript{45} Although it is not possible to distinguish whether these components originate from the myocardium or from phagocytes migrated into the myocardium, these results point towards increased oxidative stress in the infarcted heart, and a possible beneficial involvement for the effects of H\textsubscript{2}S at the later time point. Furthermore, ROS production was markedly reduced in H\textsubscript{2}S treated cardiomyoblasts in an \textit{in vitro} model of Antimycin induced oxidative stress, indicating direct scavenging or reduction in production of ROS by mitochondria. H\textsubscript{2}S has direct scavenging effects on ROS, but also has indirect effects via activation of antioxidant mechanisms, such as increasing glutathione levels.\textsuperscript{46,47} Another mechanism that could be involved is the capacity of H\textsubscript{2}S to modulate cellular respiration, as the inhibition of mitochondrial respiration has been shown to protect against myocardial IRI by limiting ROS production in mitochondria.\textsuperscript{48} Antioxidant effects of H\textsubscript{2}S may be of critical importance for the treatment of myocardial IRI because oxidative stress plays a prominent role in the development of cardiac damage and remodeling.\textsuperscript{42}

The effect of exogenous H\textsubscript{2}S on blood pressure is still under debate. \textit{In vivo} and ex \textit{vivo} studies revealed conflicting responses to H\textsubscript{2}S treatment.\textsuperscript{49-53} The effects of H\textsubscript{2}S on heart rate are also ambiguous; ranging from no change\textsuperscript{54} to decreased heart rate in others.\textsuperscript{50} Ufnal et al. noticed an increased heart rate upon NaHS infusion, however dependent on H\textsubscript{2}S concentration in cerebrospinal fluid.\textsuperscript{55} In additional support of this last view, suppression of H\textsubscript{2}S production either pharmacologically\textsuperscript{56} or genetically\textsuperscript{57} leads to an increase in blood pressure. These opposing results might be attributable to differences in dose and route of administration.

In this study we show that 100 ppm of gaseous H\textsubscript{2}S significantly lowers blood pressure and heart rate which might have affected cardiac workload and oxygen demand. Since we did not add a group with similar decrease in heart rate and blood pressure or a hypometabolic group with normal heart rate and blood pressure, we can not exclude this phenomenon to be responsible for the improved outcome. Aside from other protective effects of H\textsubscript{2}S, it is thought that the reduced demand for oxygen during hypometabolism might be one of the protective mechanisms during ischemia based on the fact that oxygen availability and oxygen expenditure are more balanced. On the other
hand the protective effects can not solely be explained by these effects since 10 ppm H\textsubscript{2}S does not alter heart rate and blood pressure and has positive effects on several damage parameters. Another approach might be local delivery of H\textsubscript{2}S by H\textsubscript{2}S-donors thereby circumventing its systemic effects, which has previously been shown to be protective\textsuperscript{15}. However, the highly volatile nature of H\textsubscript{2}S and the associated difficulties in measuring this compound make it difficult to determine the exact dose and how long its effects endure, when given locally.

In conclusion, gaseous administration of H\textsubscript{2}S protects the heart from IRI, likely through reduction of myocardial ROS production and the inhibition of inflammation, necrosis and fibrogenesis. Hypometabolism-inducing concentrations of H\textsubscript{2}S seem to have additional protective effects on necrotic cell death shortly after ischemia. H\textsubscript{2}S treatment might be of clinical use in myocardial ischemia or cardiac transplantation, where it could lead to reduced myocardial damage related to hypoxia.

**Acknowledgements**

The authors would like to express their gratitude towards Marian Bulthuis and Susanne Veldhuis for their excellent technical support.
Gaseous H₂S is protective in myocardial I/R injury

References


Gaseous H\textsubscript{2}S is protective in myocardial I/R injury


PART 2

The role of H$_2$S in diabetes and its vascular complications